Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Illumina Inc.
ILMNHealthcareGenerated Jul 5, 2026, 08:11 PM UTC
ILMN (Illumina Inc.) analytical snapshot. Revenue declined +1.7% YoY to $4.50B. Net margin at -25.78% (contracting ▼). Return on equity -17.59%, ROA -18.42%, ROIC -16.20%. Market cap $28.55B at $188.68 per share. FCF DCF intrinsic value ≈ $34.11 → implied downside +81.9%. DCF assumptions: Base FCF $283.0M; Stage-1 growth 9.42% for 5y; Terminal growth 2.50%; Discount rate 10.00%. Risk: Low. Macro: Risk-on · Supportive. Composite analytical score -16 (data confidence 82%). Descriptive analytics from public filings — not investment advice.
Free SEC analysis
— computed from SEC filings, free to readFundamentals
Revenue declined +1.7% YoY to $4.50B. Net margin at -25.78% (contracting ▼). Return on equity -17.59%, ROA -18.42%, ROIC -16.20%.
- Revenue declined +1.7% YoY to $4.50B.
- Net margin at -25.78% (contracting ▼).
- Return on equity -17.59%, ROA -18.42%, ROIC -16.20%.
- Gross margin 60.92%, operating margin -23.73%.
- Free cash flow margin 6.28% ($283.0M).
- Net income up ▲ +73.6% YoY.
- Debt/equity 0.31, current ratio 1.75, net debt -$306.0M.
- Asset turnover 0.69 — capital efficiency.
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2016 | — | — | — | — | — | $395.3M | 19.12 |
| 2017 | — | — | — | — | — | $643.0M | 21.03 |
| 2018 | $2.40B | — | 69.47 | 24.48 | 19.31 | $519.0M | 16.84 |
| 2019 | $2.75B | +14.8% | 66.35 | 22.02 | 26.38 | $565.0M | 19.32 |
| 2020 | $3.33B | +21.1% | 69.01 | 26.49 | 24.78 | $846.0M | — |
| 2021 | $3.54B | +6.3% | 69.63 | 27.80 | 28.28 | $842.0M | — |
| 2022 | $3.24B | -8.6% | 68.01 | 17.91 | 0.00 | $891.0M | 0.00 |
| 2023 | $4.53B | +39.7% | 69.69 | -2.72 | 16.84 | $337.0M | 16.23 |
| 2024 | $4.58B | +1.3% | 64.83 | -91.16 | -96.07 | $106.0M | -41.01 |
| 2025 | $4.50B | -1.7% | 60.92 | -23.73 | -25.78 | $283.0M | -17.59 |
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Mar 30, 2025 | $1.04B | — | — | 12.58% |
| Jun 29, 2025 | $2.10B | — | +101.7% | 17.43% |
| Jun 29, 2025 | $1.06B | — | -49.6% | 34.56% |
| Sep 28, 2025 | $3.18B | — | +200.7% | 16.21% |
| Sep 28, 2025 | $1.08B | — | -66.0% | 47.60% |
| Mar 29, 2026 | $1.09B | — | +0.6% | 12.28% |
Filings & Ownership
Latest annual report (10-K) filed Feb 12, 2026. Latest quarterly report (10-Q) filed May 4, 2026. 13 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 12, 2026.
- Latest quarterly report (10-Q) filed May 4, 2026.
- 13 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 9 sell transactions — net selling $365.1K.
| Insider | Date | Net | Buys/Sells |
|---|---|---|---|
| Davies Scott M | Jun 25, 2026 | -$110.7K | 0/1 |
| Leckman Patricia | Jun 9, 2026 | -$127.3K | 0/5 |
| Leckman Patricia | Jun 4, 2026 | -$127.1K | 0/3 |
| Date | Form | Description |
|---|---|---|
| Jun 23, 2026 | 8-K | 8-K |
| May 26, 2026 | 8-K | 8-K |
| Apr 30, 2026 | 8-K | 8-K |
| Apr 2, 2026 | 8-K | 8-K |
| Feb 5, 2026 | 8-K | 8-K |
| Jan 30, 2026 | 8-K | 8-K |
| Jan 13, 2026 | 8-K | 8-K |
| Jan 8, 2026 | 8-K | 8-K |
SEC Filing Deep-Analysis
1 risk signal(s), 1 positive signal(s) detected from XBRL filing diff analysis. 1 positive signal(s) versus 1 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- Gross margin compression: Gross margin contracted +3.9%pp (from 64.8% to 60.9%). This may reflect input cost inflation, pricing pressure, or product mix shift toward lower-margin segments.
- Deferred revenue growing — future revenue visibility: Deferred revenue grew +25.2% to $121.0M, providing forward revenue visibility. This is a positive leading indicator for subscription or contract-based businesses.
- Endogenous analysis: 1 positive signal(s) versus 1 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- 4 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $4.58B | $4.50B | $-80.0M | -1.7% |
| Gross profit | $2.97B | $2.74B | $-228.0M | -7.7% |
| Operating income | $-4.18B | $-1.07B | $3.11B | +74.4% |
| Net income | $-4.40B | $-1.16B | $3.24B | +73.6% |
| Operating cash flow | $392.0M | $478.0M | $86.0M | +21.9% |
| Capex | $286.0M | $195.0M | $-91.0M | -31.8% |
| Total assets | $10.11B | $6.30B | $-3.81B | -37.7% |
| Cash & equivalents | $636.0M | $769.0M | $133.0M | +20.9% |
| Stockholders equity | $10.74B | $6.60B | $-4.14B | -38.6% |
| Inventory | $587.0M | $547.0M | $-40.0M | -6.8% |
| Accounts receivable | $734.0M | $735.0M | $1.0M | +0.1% |
| R&D expense | $1.32B | $1.35B | $33.0M | +2.5% |
| SG&A expense | $1.30B | $1.61B | $315.0M | +24.3% |
| Interest expense | $49.0M | $61.0M | $12.0M | +24.5% |
| Type | Concepts |
|---|---|
| Added | BusinessCombinationContingentConsiderationLiabilityCurrent, FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear, FiniteLivedIntangibleAssetsGross, InventoryNoncurrent |
| Removed | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment, AdvertisingExpense, CapitalExpendituresIncurredButNotYetPaid, CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths, CommonStockParOrStatedValuePerShare, CommonStockSharesAuthorized, CommonStockSharesIssued, CommonStockSharesOutstanding, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit |
Unlock the rest
- ProValuationMarket cap $28.55B at $188.68 per share.
- ProPrice & TechnicalsPrice $188.68 — uptrend (above 200-DMA); 1-month momentum positive.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Low.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite -16
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Illumina Inc. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Analytical read
deterministic previewPrice $188.68 — uptrend (above 200-DMA); 1-month momentum positive..
Peer comparison
Defensive groupHow ILMN stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Cigna Group CI | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| CVS Health Corp. CVS | 6 | Neutral |
| Zoetis Inc. ZTS | 3 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Colgate-Palmolive CL | 1 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| Gilead Sciences GILD | 1 | Neutral |
| Intuitive Surgical Inc. ISRG | -1 | Neutral |
| Moderna Inc. MRNA | -4 | Neutral |
| Regeneron Pharmaceuticals REGN | -4 | Neutral |
| DexCom Inc. DXCM | -7 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Kimberly-Clark Corp. KMB | -10 | Neutral |
| Sysco Corp. SYY | -10 | Neutral |
| Danaher Corp. DHR | -11 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Biogen Inc. BIIB | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| HCA Healthcare HCA | -14 | Neutral |
| Illumina Inc. ILMN● you | -16 | Neutral |
| Kroger Co. KR | -16 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Hershey Co. HSY | -26 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |
| Thermo Fisher Scientific TMO | — | Neutral |
| Vertex Pharmaceuticals VRTX | — | Neutral |